Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental therapies for multiple sclerosis: current status.

D E Goodkin1, R M Ransohoff, R A Rudick

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195.

Cleveland Clinic Journal of Medicine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.

European journal of neurology·2020
Same author

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2015
Same author

Evidence for the contribution of adult neurogenesis and hippocampal cell death in experimental cerebral malaria cognitive outcome.

Neuroscience·2014
Same author

Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

AJNR. American journal of neuroradiology·2014
Same author

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.

British journal of cancer·2014
Same author

Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.

Clinical and experimental immunology·2013

Multiple sclerosis (MS) is a leading cause of disability in young adults, likely due to immune system dysfunction. This review examines experimental treatments for MS, discussing their efficacy and challenges in clinical trials.

Area of Science:

  • Neuroimmunology
  • Clinical Therapeutics
  • Epidemiology of Neurological Disorders

Background:

  • Multiple sclerosis (MS) is a significant cause of non-traumatic neurological disability in young adults in the U.S.
  • The exact cause of MS is unknown, but immune system dysregulation is implicated in its development.
  • Understanding MS pathogenesis is crucial for developing effective treatments.

Purpose of the Study:

  • To review the outcomes of clinical trials for experimental therapeutic agents used in treating multiple sclerosis.
  • To describe the background and mechanism of action for each reviewed treatment.
  • To analyze the clinical experience and effectiveness of these agents.

Main Methods:

  • Systematic review of clinical trial data for experimental multiple sclerosis therapies.

Related Experiment Videos

  • Analysis of treatment mechanisms and reported clinical outcomes.
  • Discussion of challenges in evaluating treatment efficacy and designing future trials.

    • Main Results:

    • Summarizes findings from various experimental therapeutic agents tested in MS patients.
    • Details the background and action of each treatment modality.
    • Presents a review of the clinical experience with each agent.

    Conclusions:

    • Experimental treatments show promise but require rigorous evaluation.
    • Challenges in clinical trial design and outcome interpretation persist.
    • Further research is needed to overcome obstacles in MS treatment development.